| 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析 |
| |
| 引用本文： | 吴凤萍,鲁瑞,刘怡欣,王怡恺,田燕,张欣,贾晓黎,党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析[J]. 实用肝脏病杂志, 2021, 24(5): 677-680. DOI: 10.3969/j.issn.1672-5069.2021.05.018 |
| |
| 作者姓名： | 吴凤萍 鲁瑞 刘怡欣 王怡恺 田燕 张欣 贾晓黎 党双锁 |
| |
| 作者单位： | 710004 西安市 西安交通大学第二附属医院感染病科 |
| |
| 基金项目： | *陕西省重点研发计划社会发展领域一般项目(编号:2020SF-297) |
| |
| 摘 要： | 目的 探讨核苷(酸)类似物(NAs)序贯联合聚乙二醇干扰素α(Peg-IFN-α)治疗血清HBsAg低水平的慢性乙型肝炎(CHB)患者的疗效和安全性.方法 2015年11月～2018年10月我院NAs经治的HBsAg≤1500 IU/mL的CHB患者106例,其中42例在继续NAs治疗的基础上联合Peg-IFNα-2a...
|
| 关 键 词： | 慢性乙型肝炎 聚乙二醇干扰素α 核苷(酸)类似物 序贯联合治疗 HBsAg清除 |
| 收稿时间： | 2020-11-17 |
Serum HBsAg clearance in sequential combination of peginterferon alpha-treated patients with chronic hepatitis B with low serum HBsAg levels after nucleos(t)ide analogs treatment |
| |
| Wu Fengping,Lu Rui,Liu Yixin,et al. Serum HBsAg clearance in sequential combination of peginterferon alpha-treated patients with chronic hepatitis B with low serum HBsAg levels after nucleos(t)ide analogs treatment[J]. Journal of Clinical Hepatology, 2021, 24(5): 677-680. DOI: 10.3969/j.issn.1672-5069.2021.05.018 |
| |
| Authors: | Wu Fengping Lu Rui Liu Yixin et al |
| |
| Affiliation: | Department of Infectious Diseases, Second Affiliated Hospital, Jiaotong University, Xi’an 710004, Shaanxi Province, China |
| |
| Abstract: | Objective The aim of this study was to analyze the efficacy and safety of sequential combination of nucleos(t)ide analogs (NAs) with peginterferon alpha (Peg-IFN-α) in the treatment of patients with chronic hepatitis B (CHB) with low serum HBsAg levels. Methods A total of 106 CHB patients with serum HBsAg levels less than 1500 IU/mL after NAs treatment were enrolled in our hospital between November 2015 and October 2018. 42 patients were given sequential combination therapy of NAs and Peg-IFNα-2a/2b for 48 weeks, and 64 patients were continuously treated with NAs who had always taken. All patients were followed-up to week 96 (48 weeks after discontinuation of Peg-IFN-α). Results Two patients in the sequential combination group and 4 patients in the NAs group were lost; the intention- to-treat (ITT) analysis showed that the baseline materials in the two groups were comparable; serum HBsAg clearance rate and anti-HBs seroconversion rate in the sequential combination group were 19.0% and 14.3% at the end of 48-week treatment, both significantly higher than 0.0% and 0.0%, respectively, in the NAs group (P <0.001); the rates of serum HBsAg clearance and anti-HBs seroconversion at the end of 48-week follow-up in the sequential combination group were 21.4% and 19.0%, both significantly higher than 1.6% and 1.6%,respectively (P <0.001)in the NAs group; the liver stiffness measurement (LSM) was (7.2±0.3) kPa, significantly lower than in the NAs group, Conclusion The sequential combination of NAs and Peg-IFN-α treatment ameliorate serum HBsAg clearance and seroconversion, which might improve liver fibrosis in CHB patients with low levels of HBsAg, and gain clinical recovery. |
| |
| Keywords: | Hepatitis B Peginterferon alpha Nucleos(t)ide analogs Sequential combination Serum HBsAg clearance |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《实用肝脏病杂志》浏览原始摘要信息 |
|
点击此处可从《实用肝脏病杂志》下载免费的PDF全文 |
